Quest Partners LLC Acquires 3,150 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Quest Partners LLC increased its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 30.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,510 shares of the company’s stock after acquiring an additional 3,150 shares during the quarter. Quest Partners LLC’s holdings in Replimune Group were worth $122,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of REPL. Price T Rowe Associates Inc. MD increased its holdings in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares during the period. Vanguard Group Inc. raised its holdings in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after acquiring an additional 32,555 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock worth $18,874,000 after acquiring an additional 1,679,553 shares during the period. Rafferty Asset Management LLC lifted its position in shares of Replimune Group by 148.1% in the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after acquiring an additional 276,596 shares during the period. Finally, Sectoral Asset Management Inc. grew its holdings in shares of Replimune Group by 12.7% during the 4th quarter. Sectoral Asset Management Inc. now owns 305,412 shares of the company’s stock worth $2,575,000 after purchasing an additional 34,356 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REPL has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Monday. Wedbush reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a report on Thursday, June 6th. Barclays upped their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. JPMorgan Chase & Co. cut their price target on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price target of $16.20.

Insider Activity

In related news, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 20.60% of the stock is currently owned by corporate insiders.

Replimune Group Price Performance

NASDAQ:REPL opened at $10.46 on Tuesday. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market cap of $714.63 million, a PE ratio of -3.23 and a beta of 1.22. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $18.12. The company’s 50-day moving average price is $10.15 and its two-hundred day moving average price is $8.37.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. On average, equities analysts anticipate that Replimune Group, Inc. will post -3.08 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.